Curcumin C3 Reduct® contains high bioavailability curcumin, demethoxycurcumin and bisdemethoxycurcumin metabolites with 95% tetrahydrocurcuminoids.
Assessed by EFSA as safe for the target population at a dose of 140 mg per day.
Curcumin C3 Reduct® is the focus of clinical research for the management of several lifestyle-related conditions: arthritis, liver disorders, inflammation, hypercholesterolemia, among others, due to its antioxidant and anti-inflammatory properties.
Curcumin, the main source of curcuminoids from the spice turmeric, has gained increasing global recognition for its multiple health benefits, particularly its antioxidant and anti-inflammatory properties. As a result, the ingredient is used as a means to support health and longevity.
Specifically turmeric (Curcuma longa):
- It prevents the accumulation of fats and facilitates their elimination by the liver.
- Helps maintain liver health.
- Helps maintain the health of the lungs and upper respiratory tract.
- Helps maintain the effectiveness of the immune system.
- Helps maintain allergy resistance.
- Antioxidant / Protects from free radicals.
- Supports nervous system function.
- Supports heart function.
- Supports blood circulation.
- Helps keep skin healthy.
- It is used to stimulate appetite.
- Helps promote appetite in cases of appetite loss.
A primary advantage of Curcumin C3 Reduct is that these health benefits are concentrated and enhanced. In C3 Reduct, curcuminoids are in the form of tetrahydrocurcuminoids (THC). That is, the product is assimilated directly into the body as beneficial metabolites.
This is important as the metabolites are more bioavailable than the original curcuminoids.
In fact, C3 Reduct is the only EFSA-approved product of its kind on the market.
This is because C3 Reduct delivers active metabolites directly to the body.
Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014 Dec 1;19(12):20091-112. doi: 10.3390/molecules191220091. PMID: 25470276; PMCID: PMC6270789.
Sahebkar, Amirhossein & Serban, Maria-Corina & Ursoniu, Sorin & Banach, Maciej. (2015). Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis. 241. e189–e190. 10.1016/j.atherosclerosis.2015.04.931.
Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10. PMID: 23143785; PMCID: PMC3535097.
Aggarwal, Bharat & Kumar, Anushree & Bharti, Alok. (2002). Anticancer Potential of Curcumin: Preclinical and Clinical Studies. Anticancer research. 23. 363-98.
Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica. 1978 Dec;8(12):761-8. doi: 10.3109/00498257809069589. PMID: 726520.
Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica. 1978 Dec;8(12):761-8. doi: 10.3109/00498257809069589. PMID: 726520.
Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20. doi: 10.1073/pnas.1016217108. Epub 2011 Apr 5. PMID: 21467222; PMCID: PMC3080977.
Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J Pharmacol Exp Ther. 2008 Jul;326(1):196-208. doi: 10.1124/jpet.108.137455. Epub 2008 Apr 16. PMID: 18417733; PMCID: PMC2527621.
Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol. 2005;16(4):257-74. doi: 10.1515/jbcpp.2005.16.4.257. PMID: 16438392.
Pari L, Murugan P. Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail. 2007;29(7):881-9. doi: 10.1080/08860220701540326. PMID: 17994458.
Lai CS, Wu JC, Yu SF, Badmaev V, Nagabhushanam K, Ho CT, Pan MH. Tetrahydrocurcumin is more effective than curcumin in preventing azoxymethane-induced colon carcinogenesis. Mol Nutr Food Res. 2011 Dec;55(12):1819-28. doi: 10.1002/mnfr.201100290. Epub 2011 Sep 2. PMID: 21887819.
Wu Y, Chen Y, Ye X, Guo X, Sun L, Zou J, Shen Y, Mao Y, Li C. 2021. Tetrahydrocurcumin alleviates allergic airway inflammation in asthmatic mice by modulating the gut microbiota. Food and Function. 12 (15): 6830 – 6840
Pari L, Murugan P. Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail. 2007;29(7):881-9. doi: 10.1080/08860220701540326. PMID: 17994458.
Pari L, Murugan P. Influence of tetrahydrocurcumin on tail tendon collagen contents and its properties in rats with streptozotocin-nicotinamide-induced type 2 diabetes. Fundam Clin Pharmacol. 2007 Dec;21(6):665-71. doi: 10.1111/j.1472-8206.2007.00542.x. PMID: 18034669.
Majeed M, Majeed S, Nagabhushanam K. Efficacy and Safety of Tetrahydrocurcuminoids for the Treatment of Canker Sore and Gingivitis. Evid Based Complement Alternat Med. 2020 Dec 16;2020:6611877. doi: 10.1155/2020/6611877. PMID: 33381205; PMCID: PMC7758131.
Chhaparwal, Yogesh & Pai, Keerthilatha & Kamath, M.s & Carnelio, Sunitha & Chhaparwal, Shubha. (2018). Efficacy and safety of tetrahydrocurcuminoid in the treatment of oral leukoplakia: A pilot study. Asian Journal of Pharmaceutical and Clinical Research. 11. 194. 10.22159/ajpcr.2018.v11i12.28107.
Zhang ZB, Luo DD, Xie JH, Xian YF, Lai ZQ, Liu YH, Liu WH, Chen JN, Lai XP, Lin ZX, Su ZR. Curcumin’s Metabolites, Tetrahydrocurcumin and Octahydrocurcumin, Possess Superior Anti-inflammatory Effects in vivo Through Suppression of TAK1-NF-κB Pathway. Front Pharmacol. 2018 Oct 17;9:1181. doi: 10.3389/fphar.2018.01181. PMID: 30386242; PMCID: PMC6199526.
Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats
Kim T, Davis J, Zhang AJ, He X, Mathews ST. Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Biophys Res Commun. 2009 Oct 16;388(2):377-82. doi: 10.1016/j.bbrc.2009.08.018. Epub 2009 Aug 8. PMID: 19665995.